Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ispinesib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 known ✓ | P52732 | 16/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.67 |
| ▸ | PDE6D | O43924 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ispinesib SCHEMBL15810599 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL370194 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL29375933 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL2963210 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL29711229 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6360968 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6349230 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL14264772 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6351736 | 0.92 | KIF11 (0.85) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL17322993 | 0.92 | KIF11 (0.84) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | claimed |
| WO-2025233679-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND ANTIBODY DRUG CONJUGATES | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | claimed |
| EP-4615576-A1 | CELLS BEING HIGHLY ENRICHED IN SASP FACTORS, AND COMPOSITION COMPRISING SAID CELLS | Evomedis GmbH (AT) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | claimed |
| CN-118525105-A | High ATP affinity proteins and inhibitors thereof as targets for treatment of refractory molecular subtype cancers | 维拉沃斯公司 | 2024-08-20 | — | — | CN | claimed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024104577-A1 | CELLS BEING HIGHLY ENRICHED IN SASP FACTORS, AND COMPOSITION COMPRISING SAID CELLS | EVOMEDIS GMBH (AT) | 2024-05-23 | — | — | WO | claimed |
| WO-2023085716-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | 연세대학교 산학협력단 | 2023-05-19 | — | — | WO | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | claimed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | claimed |
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | FINER JEFFREY T (US) | 2013-02-28 | — | — | US | claimed |
| US-20100063073-A1 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INC. | 2010-03-11 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20060041130-A1 | Syntheses of quinazolinones | CYTOKINETICS, INC. AND SMITHKLINE BEECHAM CORP. | 2006-02-23 | — | — | US | disclosed |
| US-20040067969-A1 | Syntheses of quinazolinones | CYTOKINETICS, INCORPORATED | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067969-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885MAP1LC3B 544/4885KCNH2 941/4885 |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | KIF11 4529/4885MAP1LC3B 3655/4885KCNH2 3766/4885 |
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | KIF5B, KIF5C, KIF2C | KIF11 22/4885MAP1LC3B 79/4885KCNH2 1101/4885 |
| US-20100063073-A1 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | KIF5B, KIF2C, KIF18B | KIF11 12/4885MAP1LC3B 106/4885KCNH2 467/4885 |
| US-20060041130-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885MAP1LC3B 544/4885KCNH2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.